

Daftar Pustaka

1. Thandra KC, Barsouk A, Saginala K, Aluru JS, Barsouk A. Epidemiology of lung cancer. *Contemp Oncol*. 2021;25(1):45-52.
2. Davalos AR, Coppe JP, Campisi J, Desprez PY. Senescent cells as a source of inflammatory factors for tumor progression. *Cancer Metastasis Rev*. 2010;29(2):273–83.
3. Zhao Y, Jia S, Zhang K, Zhang L. Serum cytokine levels and other associated factors as possible immunotherapeutic targets and prognostic indicators for lung cancer. *Front Oncol*. 2023;13(Feb):1–12.
4. Haura EB, Livingston S, Coppola D. Autocrine interleukin-6/interleukin-6 receptor stimulation in non-small-cell lung cancer. *Clin Lung Cancer*. 2006;7(4):273–5.
5. Califf RM. Biomarker definitions and their applications. *Exp Biol Med*. 2018;243(3):213–21.
6. Food and Drug Administration (FDA); NIH. BEST (Biomarkers, EndpointS, and other Tools) Resource. 2016. <https://www.ncbi.nlm.nih.gov/books/NBK326791/>
7. Šutić M, Vukić A, Baranašić J, Försti A, Džubur F, Samaržija M, et al. Diagnostic, predictive and prognostic biomarkers in non-small cell lung cancer (KPKBSK) management. *J Pers Med*. 2021;11(11).
8. Garon EB, Yang JC, Dubinett SM. The Role of Interleukin 1 β in the Pathogenesis of Lung Cancer. *JTO Clin Res Reports*. 2020;1(1):100001.
9. Garinet S, Wang P, Mansuet-Lupo A, Fournel L, Wislez M, Blons H. Updated Prognostic Factors in Localized KPKBSK. *Cancers (Basel)*. 2022;14(6).
10. Moon Y, Lee KY, Sung SW, Park JK. Differing histopathology and prognosis in pulmonary adenocarcinoma at central and peripheral locations. *J Thorac Dis*. 2016;8(1):169–77.
11. Wang L, Zhou Y, Wang G, Liu D, Chen B, Pu D, et al. Clinical features and prognostic factors of combined small cell lung cancer. *Transl Lung Cancer Res*. 2021;10(11):4250.



12. Silver Spring (MD): FDA (US); Bethesda (MD): NIH (US). BEST (Biomarkers, EndpointS, and other Tools) Resource. 2016.
13. Crossman D, Rothman AMK. Interleukin-1 beta inhibition with canakinumab and reducing lung cancer—subset analysis of the CANTOS trial. *J Thorac Dis.* 2018;10(Suppl 26):S3084.
14. Tanaka T, Narazaki M, Kishimoto T. IL-6 in Inflammation, Immunity, and Disease. 2014;6:1–16.
15. An J, Gu Q, Cao L, Yang H, Deng P, Hu C, Li M. Serum IL-6 as a vital predictor of severe lung cancer. *Ann Palliat Med.* 2021;10(1):202–209.
16. Rose-John S. Interleukin-6 family cytokines. *Cold Spring Harb Perspect Biol.* 2018;10(2):1–17.
17. Kang S, Narazaki M, Metwally H, Kishimoto T. Historical overview of the interleukin-6 family cytokine. *J Exp Med.* 2020;217(5):1–10.
18. Qu Z, Sun F, Zhou J, Li L, Shapiro SD, Xiao G. Interleukin-6 prevents the initiation but enhances the progression of lung cancer. *Cancer Res.* 2015;75(16):3209–15.
19. Rašková M, Lacina L, Kejík Z, et al. The Role of IL-6 in Cancer Cell Invasiveness and Metastasis—Overview and Therapeutic Opportunities. *Cells.* 2022;11(22):3698.
20. Liu C, Yang L, Xu H, et al. Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer. *BMC Med.* 2022;20:187.
21. Rice SJ, Liu X, Zhang J, Jia B, Zheng H, Belani CP. Advanced NSCLC patients with high IL-6 levels have altered peripheral T cell population and signaling. *Lung Cancer.* 2019;131:58–61.
22. Yan X, Han L, Zhao R, Fatima S, Zhao L, Gao F. Prognosis value of IL-6, IL-8, and IL-1 β in serum of patients with lung cancer: A fresh look at interleukins as a biomarker. *Heliyon.* 2022;8(8):e09953.
23. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). *Eur J Cancer.* 2009;45(2):228–47.



elazquez-Salinas L, Verdugo-Rodriguez A, Rodriguez LL, Borca MV. The role of interleukin 6 during viral infections. *Front Microbiol.* 2019;10(MAY):6–11.

ang H, Bai Y, Shen W, Zhao J. Research progress on interleukin-6 in lung cancer. *J Zhejiang Univ.* 2018;47(6):659–64.

26. Iftikhar N, Shaukat F, Khan H. Serum and Bronchoalveolar Lavage Fluid Levels of Cytokines in Lung Cancer Patients. *Medicina (Kaunas)*. 2023;59(7):1234.
27. Zhu J, Chen Y, Wang T, Zhang Y. TGF- β 1, IL-6 and TNF- α in Bronchoalveolar Lavage Fluid as Potential Biomarkers for Lung Cancer. *Sci Rep*. 2023;13:5595.
28. Martínez-Morillo E, Sierra-Cote MC, Alonso MH. Evaluation of IL-6 Level in Serum and Bronchoalveolar Lavage Fluid of Patients with Non-Small Cell Lung Cancer (NSCLC). *Eur Respir J*. 2023;38(Suppl 55):P2798.
29. Sukmawaty. Analisis Kadar Interleukin-6 Cairan Bilasan Bronkus Pasien Kanker Paru. Tesis, Universitas Hasanuddin; 2017.
30. Wang M, et al. IL-6 as a Biomarker in Lung Cancer: A Meta-Analysis. *Eur Respir J*. 2019;54:1802476.
31. Gao S, et al. Age-Related Changes in Inflammatory Profiles in Lung Cancer. *Int J Mol Sci*. 2020;21(3):1075.
32. Zhang H, et al. IL-6 Levels in Chronic Inflammation and Cancer Progression. *Front Immunol*. 2021;12:717953.
33. Lee CH, et al. Smoking and IL-6 in Lung Cancer Pathogenesis. *J Thorac Oncol*. 2020;15(8):1223–34.
34. Sun Y, et al. Inflammatory Mediators in Tobacco Smoke-Induced Lung Injury. *J Immunol Res*. 2022;2022:8175453.
35. Barnes PJ. Inflammatory Mechanisms in COPD and Lung Cancer. *Eur Respir J*. 2018;51(6):1702168.
36. Kim J, et al. Role of IL-6 in Prognosis of Lung Cancer Patients. *Oncotarget*. 2021;12(5):490–502.
37. Smith RA, et al. Diagnostic Value of IL-6 in Lung Cancer: A Systematic Review. *Respir Res*. 2022;23(1):50.
38. Munawwar S. Analisis Kadar Interleukin-6 (IL-6) Serum Terhadap Kesintasan Pada Pasien Kanker Paru Jenis Karsinoma Bukan Sel Kecil (KPKBSK) Stadium Lanjut. Tesis. Universitas Hasanuddin; 2021.





Optimized using
trial version
www.balesio.com